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Abstract
Thyroid-associated ophthalmopathy (TAO) is a condition associated with a wide spectrum of ocular changes,
usually in the context of the autoimmune syndrome, Graves’ disease. In this topical review, we attempted to
provide a roadmap of the recent advances in current understanding the pathogenesis of TAO, important aspects of
its clinical presentation, its impact on the ocular surface, describe the tissue abnormalities frequently encountered,
and describe how TAO is managed today. We also briefly review how increased understanding of the disease
should culminate in improved therapies for patients with this vexing condition.
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Background
Thyroid-associated ophthalmopathy (TAOa, aka thyroid
eye disease or Graves’ ophthalmopathy) refers to several
ocular manifestations related to the systemic auto-
immune process, Graves’ disease (GD) [1]. This syn-
drome has been attributed to the loss of immune
tolerance to the thyrotropin receptor (TSHR) and per-
haps other auto-antigenic proteins [2, 3]. TAO results
from the linked conspiracy of auto-reactivity and tissue
remodeling. The factors that over-arch the ocular com-
ponents of GD with the pathology occurring in the thy-
roid have yet to be identified unambiguously. TAO is the
most common and serious extra-thyroidal manifestation
of GD, with 25–50% in those with the thyroid disease
[4–6]. While the majority of individuals with GD be-
come hyperthyroid sometime in the course of their dis-
ease, TAO can also occur in primary hypothyroidism
and in patients who remain euthyroid [7]. Substantial
evidence suggests that GD and TAO result from com-
plex interplay between genetic susceptibility, epigenetic
factors, and several partially characterized environmental
triggers [8]. Several recent reviews have addressed TAO;
however none has detailed insights of the association
and interactions between TAO, the ocular surface (OS)
and dry eye syndrome (DES). We have thus included an
emphasis on the OS and DES in this review.
Pathogenesis
The central participant in the pathogenesis of TAO is
the orbital fibroblast [9, 10]. Orbital fibroblasts from
healthy individuals appear to differ from those with TAO
[11–13]. They represent a heterogeneous population of
cells with divergent capacities for terminal differentiation
and gene expression. We now know that a subpopula-
tion of orbital fibroblasts in TAO derive from bone mar-
row derived fibrocytes [14]. These cells express several
thyroid antigens that have been implicated in TAO.
Among them is the TSHR. TSHR has been detected in
orbital connective tissue and on orbital fibroblasts, albeit
at extremely low levels [15, 16] but the basis for its ex-
pression has remained uncertain. Fibrocytes were found
to infiltrate the TAO orbit and express higher levels of
TSHR than those found on orbital fibroblasts [14, 17, 18].
Furthermore, the receptor displayed on fibrocytes is func-
tional in that TSH and thyroid-stimulating immunoglobu-
lins (TSI) provoke the generation of extremely high levels
of inflammatory cytokines. These include IL-6, TNF-α, IL-
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8, and IL-1β [19]. How the receptor participates in TAO is
less certain. In addition to TSHR, other thyroid autoanti-
gens have also been detected in orbital tissues and
expressed by orbital fibroblasts [8]. Persistence of detect-
able thyroid autoantibodies in patients with therapy-
resistant TAO may support a role for these autoantigens
in disease pathogenesis [20].
It is unclear how the abnormal behavior of orbital fi-
broblasts in TAO interplays with the recruited lympho-
cytes, mast cells and macrophages. Their accumulation
in the orbit is characteristic of the disease. Development
of their therapeutic targeting is of considerable import-
ance [12, 18]. Subpopulations of orbital fibroblasts may
explain, at least in part, the diversity of clinical TAO
presentation. The disease can manifest as predominantly
fat expansion or with isolated extraocular muscle (EOM)
involvement or most commonly a mixture of both [13, 21].
Fibroblasts can be identified on the basis of cell surface
markers such as Thy-1 and CD34. Subsets differ in
their ability to differentiate into adipocytes or myofi-
broblasts [13, 22]. Cells from orbital fat differ pheno-
typically from those of perimysial derivation [23].
TAO is associated with accelerated glycosaminoglycan
production, resulting in mechanical embarrassment of
the orbital contents [14, 24, 25]. Orbital fibroblast prolif-
eration and differentiation into adipocytes leads to fat
tissue expansion. In muscle, increased glycosaminogly-
can accumulation can interfere with normal contraction
and movement [9, 14, 25]. In advanced stages of the dis-
ease, fibrotic changes can affect muscle functions, result-
ing in restricted eye movement.
Many clinical signs and symptoms of TAO arise from
expansion of soft-tissues within the orbit, leading to
exophthalmos [9, 25, 26]. Disturbance of the ocular sur-
face is caused by inadequate lid coverage; the increased
palpebral fissure width results in accelerated tear evapor-
ation and elevated tear osmolarity [27, 28], perpetuating
an inflammatory cycle [29] and contributing to a major
source of disease morbidity.
Eyelid structures are also altered in TAO, resulting
in retraction of both upper and lower eyelids. Three
different mechanisms have been proposed [24]. The
cicatricial and restrictive theory is explained by the
effects of TAO on EOM and on the elastic compo-
nents of eyelid retractor muscles. Enlarged inferior
rectus muscle dimension and the generalized orbit
connective tissue congestion may retract the lower
eyelid margin. This is due to increased tension on
the lower eyelid complex (inferior oblique muscle, in-
ferior rectus muscle and the capsulopalpebral fascia
(CPF). In the upper eyelid, fibrosis of the Müller and
levator palpebrae superioris muscles (LPS) is variable.
Muscle hyperaction results from increased sympa-
thetic stimulation of the inferior tarsal muscle (lower
eyelid) or Müller’s muscle (upper eyelid). This is
thought to be a consequence of direct thyroid hor-
mone actions. The concept of anterior globe dis-
placement as a mechanism for eyelid retraction
resulting from proptosis is demonstrated by improve-
ment of eyelid retraction following surgical correc-
tion of proptosis [24, 30, 31]. Overall, these theories
appear compatible with the variations of clinical dis-
ease presentation.
Clinical presentation
The onset of ocular symptoms/signs and hyperthyroid-
ism can occur simultaneously or diverge temporally by
months to years [32]. Patients undergo an initial period
where inflammation, progressive orbital congestion, and
variably worsening proptosis evolve. This stage is termed
the active phase. The activity of the disease can be
assessed by calculating the clinical activity score (CAS),
based on seven signs (Table 1). In addition, clinical
severity can be classified using the NOSPECS score
(Table 2). According to Rundle’s curve, this phase can
last from months to several years [33]. Activity gives way
to a period of stabilization and ultimately leads to the in-
active phase where the disease no longer progresses.
This stable phase is seldom associated with a complete
normalization of ocular changes [4].
Proptosis or exophthalmos occurs as a consequence of
expanding orbital contents being confined within the
boney orbit and the naturally occurring decompression
resulting from anterior displacement of the globe. TAO
is the most common cause of both unilateral and bilat-
eral proptosis in adults. Pseudo-ptosis and true ptosis
may be seen in patients with TAO. The former results
from contralateral lid retraction but true ptosis occurs
when the levator muscle suffers dehiscence or when
concurrent myasthenia gravis is manifested. Strabismus
is common in TAO, resulting from restrictive extraocu-
lar muscle impairment. It can induce head tilt and diplo-
pia. The inferior and medial rectus muscles are most
commonly involved in TAO, resulting in horizontal and
vertical deviations. The basis for this predilection has
not been identified [23]. Diplopia develops from inflam-
mation and swelling of the extraocular muscles and is
generally restrictive. It is classified as intermittent
(present upon awakening or during fatigue, present at
extremes of gaze) or constant when present in primary
gaze and/or reading position [4, 9]. One other important
sign of EOM involvement is the elevation of IOP in
upgaze, due to the restrictive action of the fibrotic infer-
ior rectus muscles and blockade of the episcleral aque-
ous outflow. Orbital congestion also contributes to this
elevation IOP [34, 35]. Attention should be paid to the
position of the eye during applanation tonometry, which
must be performed in the standard position and in
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down-gaze [36]. Upper-eyelid retraction (Dalrymple
sign), often with temporal flare and scleral show, is one
the most common ocular signs of TAO and should be
differentiated from proptosis. Lid lag on down-gaze (von
Graefe sign) is another important feature of the disease,
manifesting as a downward saccadic movement with
reduced amplitude [24]. Anterior segment signs in TAO
include superficial punctate keratitis, superior limbic
keratoconjunctivitis, conjunctival injection usually over
the rectus muscle insertions and chemosis. Severe prop-
tosis can cause corneal ulceration.
Vision disturbances in severe TAO may occur due to
compressive optic neuropathy or dysthyroid optic neur-
opathy (DON). DON is defined as impairment of optic
nerve function due to compression [37]. It presents as
blurred vision, visual loss, dyschromatopsia, or field loss
and can occur in up to 5% of patients with TAO [25, 38].
Visual impairment in TAO, resulting from dysfunction of
the optic nerve, is caused by raised intraorbital pressure
due to inflammation [39, 40]. Patients with optic nerve
compression may not exhibit marked proptosis, but these
individuals usually show substantially increased resistance
to retropulsion. In addition, most cases of DON occur
without visible optic nerve edema, making frequent docu-
mentation of visual acuity, color vision, and pupillary light
reflex essential [4]. Due to orbital congestion, choroidal
folds may also be seen in TAO, among other warning signs.
These include corneal opacity, important lagophthalmos,
and pale, swollen optic discs, which can signal impending
DON [37]. Therefore, these are important to detect when
evaluating patients with TAO. DON is the most serious
quality of life-threatening condition associated with TAO
[41], and requires immediate treatment [37].
The ocular surface in TAO
A frequently underappreciated casualty of TAO is the
ocular surface, a functional unit comprising the corneal
and conjunctival epithelium, lid margins and tear film.
Classically, increased palpebral fissure width and lid alter-
ations caused by TAO have been implicated in the disrup-
tion of ocular surface homeostasis. This leads to corneal
exposure, tear film instability, accelerated tear evaporation
and high tear osmolarity [27, 28]. Eventually, ocular sur-
face inflammation ensues, initiating a vicious cycle which
eventually leads to dry eye syndrome (DES) [29].
Exophthalmos, with the resulting increased fissure
width, lagophthalmos, and poor Bell’s phenomenon can
contribute to DES. Inflammation of the OS and dry eye
are frequently associated with TAO, sometimes preced-
ing ophthalmic changes [42, 43].
In one report, patients with occult TAO consistently re-
ported symptoms of ocular irritation, including foreign
body sensation, redness, and excessive tearing [7]. These
individuals were found to have OS inflammation in the
absence of exophthalmos, lid retraction, dysmotility, and
diplopia. Thus, the earliest forms of TAO may be confined
to the OS, well in advance of lid retraction and lid lag.
A significant correlation was found between TAO ac-
tivity, measured by CAS, and OS damage, detected by
Table 2 TAO Eye changes classification - NOSPECS
NOSPECS
Class Grade Criteria
1 No physical signs or symptoms
Only signs (limited to upper lid retraction, stare, and lid lag)





3 Proptosis ≥3 mm above upper normal limit
0 Absent
a 3–4 mm increase over upper normal
b 5–7 mm increase
c ≥8 mm increase
4 Extraocular muscle involvement
0 Absent
a Limitation of motion extremes of gaze
b Evident restriction of motion
c Fixation of a globe or globes
5 Corneal involvement
0 Absent
a Stippling of cornea
b Ulceration
c Clouding, necrosis, perforation
6 Sight loss (optic nerve involvement)
0 Absent
a Disc pallor or visual field deffect; vision 20/20–20/60
b Same as 6a, but vision 20/70–20/200
c Blindness, i.e., failure to perceive light, vision < 20/200
Table 1 Clinical activity score
GO activity (CAS)
1 Spontaneous retrobulbar pain
2 Pain on attempted upward or downward gaze
3 Redness of eyelids
4 Redness of conjunctiva
5 Swelling of caruncle or plica
6 Swelling of eyelids
7 Swelling of conjunctiva (chemosis)
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lissamine green staining [44]. In that study, the preva-
lence of dry eye was 65% in patients with TAO, and his-
topathologic changes in the conjunctiva were consistent
with dry eye syndrome.
Gupta et al. [7] detected conjunctival and episcleral in-
flammation localized over the extraocular muscles in
their entire series of patients and considered it to repre-
sent a presenting sign of TAO. Subtle widening of the
inter-palpebral fissure was found in 48%, meibomian
gland dysfunction in 48%, and a decreased tear break-up
time (TBUT of less than 10 s) in 31% of these patients.
Corneal and conjunctival vital staining, indicators of
ocular surface damage, are a frequent sign in patients
with TAO [7, 19, 28, 45].
Patients also present with reduced tear break-up time
[19, 28], which indicates greater tear film instability. The
Schirmer test, which assesses basal and reflex aqueous
tear film production, may be normal [28] or reduced
[19].
Clinical diagnosis of DES in TAO
Diagnosis of DES can be made using simple, minimally
invasive tests that are routinely conducted as part of the
ophthalmological examination. These include adminis-
tration of a questionnaire that assesses symptoms of
ocular irritation and environmental triggers, such as the
OS disease index (OSDI). TBUT, a procedure involving
the instillation of fluorescein on the ocular surface, mea-
sures tear stability and exhibits the greatest correlation
with other tests for DES diagnosis [44]. The Schirmer
test, detects aqueous deficient dry eye with good sensi-
tivity [46]. Fluorescein and lissamine green staining de-
tect de-epithelized and devitalized ocular surface areas,
respectively [45].
TAO, lacrimal gland and the ocular surface
Lacrimal gland (LG) involvement in TAO may result
from the direct effects of TSI, since acinar cells of the
LG express TSHR [47]. Thyroid, salivary and lacrimal
glands resemble one another histologically [48]. Further,
all are particularly susceptible to immunological damage
[49]. Sjögren’s syndrome (SS), an autoimmune disease
characterized by chronic lymphocytic infiltration of LG
and salivary glands [50], frequently affects patients with
thyroiditis [49]. Histopathologic lesions in both diseases
are infiltrated by T cells [51]. Patients with SS have a 74-
fold greater chance of developing GD than the general
population [52]. In TAO, TNF-α increases Fas expres-
sion on lacrimal cells, resulting in apoptosis and release
of a fragment of α-fodrin [53].
Proteomic analysis of tear film can inform pathology
occurring within lacrimal glands [54, 55]. Protective fac-
tors such as proline-rich proteins (PRPs) and cystatins
were markedly down-regulated in patients with TAO
compared to healthy individuals and those with DES
[56]. Altered regulation of proinflammatory and protect-
ive proteins found in tears may reflect an inflammation-
induced dysfunction of the LG in TAO [55]. Tear pro-
teins were markedly different in those with TAO versus
other forms of DES. These include proteins involved in
inflammatory response, cell-to cell signaling and inter-
action, cellular motility and cell death. These findings
suggest that different mechanisms induce LG and OS al-
terations in TAO [56].
Levels of IL-1β, IL-2, IL-6, IL-8, IL-10, IL-17, TNF-α
and INF-γ were higher in tears from patients with active
vs stable TAO. Further, cytokine levels generally corre-
lated with CAS scores and fluorescein staining [19].
Direct autoimmune targeting in active TAO may con-
tribute to the ocular surface disease, as is evidenced by
detection of cytokines in tears [19] and active kerato-
cytes, a putative biomarker for OS inflammation [57],
respectively.
Diagnostic considerations
The frequency and severity of TAO may be lessening in
newly diagnosed GD hyperthyroidism. Further, TAO
rarely progresses to more severe disease [58]. On the other
hand, some patients, especially those exposed to tobacco,
continue to present with severe disease and others mani-
fest reactivation. Even in the absence of clinical ocular
manifestations, imaging reveals subtle orbital changes in
most patients with GD [4]. In nearly 70% of asymptom-
atic, hyperthyroid adults with GD, magnetic resonance
imaging (MRI) and computed tomographic (CT) scanning
reveal extra-ocular-muscle enlargement [9].
The most frequent clinical features of TAO are upper
eyelid retraction, periorbital edema/erythema, and prop-
tosis [9]. It is important to differentiate TAO from other
common conditions that present similarly. These include
orbital and pre-septal cellulitis, carotid cavernous fistula,
orbital pseudotumor, and thickened muscles conditions
such as sarcoidosis, neoplastic diseases and amyloid.
In most cases, the diagnosis of TAO can be established
clinically. However, imaging studies may be required to
evaluate orbit structures and aid in formulating an opti-
mal treatment plan. It is possible to evaluate optic nerve
compression on MRI and the orbital bony structure on
CT. Neuroimaging usually reveals muscle enlargement
with tendon sparing and fat expansion. Imaging may
also reveal dilated superior ophthalmic veins and apical
crowding of the optic nerve [59].
Management of TAO
General principles
Optimal care of patients with TAO requires a multidiscip-
linary approach. This usually includes both endocrinologists
and ophthalmologists who typically provide primary care.
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Other specialists should participate as needed [60, 61]. Sev-
eral academic centers have assembled multidisciplinary
teams to facilitate treatment decisions and provide follow-
up patient care, education, and family support [60, 61]. This
is true here at the University of Michigan.
Restoration and maintenance of the euthyroid state
is essential for all patients with TAO since wide
swings in thyroid function can negatively impact its
course [4, 60, 62]. Anti-thyroid drugs and surgical
thyroidectomy are extremely effective for managing
hyperthyroidism. Radioiodine treatment confers a
small additional risk of exacerbating TAO or provok-
ing its development de novo, particularly in those
who smoke tobacco and in patients with severe
hyperthyroidism. Immunosuppressive therapies such
as B cell depletion with rituximab may prove effective
and should be overseen by a collaborating rheuma-
tologist/clinical immunologist [60, 62].
Patients with GD must be given all the necessary re-
sources and guidance to achieve smoking cessation, irre-
spective of their ocular disease status. It should be
considered a primary goal in the therapeutic plan. Exposure
to smoke represents the single most modifiable environ-
mental risk factor thus far identified for TAO [4, 60, 61].
Although the mechanisms responsible for its negative im-
pact are not completely clarified, studies suggest that oxida-
tive stress might represent the culprit, by inducing the
expression of fibrosis-related genes and the increase of
intracellular pro-inflammatory cytokines [63]. Smoking can
lead to progression of TAO, smokers generally have more
severe disease, and immunosuppressive treatment is typic-
ally less effective in smokers [60, 62, 64, 65]. Advanced age
of onset, duration and severity of thyrotoxicosis, and smok-
ing are risk factors [66]. Treatment with anti-thyroid medi-
cation was negatively correlated with developing TAO but
smoking increased statistically the odds for the disease.
Older patients with restricted ocular motility, strabismus,
and active TAO are at higher risk of DON and may benefit
from early medical intervention [66].
Selenium supplementation may provide benefit for
mild cases of TAO; some patients experience improved
quality of life and reduced eye symptoms [67, 68]. One
study reported a positive effect in mild disease after a 6-
month exposure to 100 mcg daily dosage [67]. Limita-
tions of that study included a failure to analyze the back-
ground dietary intake of selenium and to determine
whether the subjects in the study geographic regions
were depleted of the element [60, 67, 68]. Another study
failed to detect a correlation between decreased serum
Selenium levels and increased TAO severity [69].
Treatments for DES and ocular surface disease in TAO
should be personalized. Baseline treatment consists of artifi-
cial tears, moisturizing ointments, and supportive measures
such as moisture chamber glasses, humidifiers, and
protection from wind and smoke [60]. Topical anti-
inflammatory therapy may prove beneficial in ocular sur-
face disease.
Therapy of active, moderate to severe TAO
Active TAO typically follows a 2 to 3-year course follow-
ing Rundle’s curve that includes inflammatory signs,
progression, and becomes “static at a level of incomplete
recovery” [33]. Depending on its severity, active TAO
can be followed with conservative measures [61]. Ocular
surface lubrication must be preserved and artificial tears,
gels and topical cyclosporine may be useful [70]. Topical
treatment may prove insufficient to ensure corneal pro-
tection. In that case, lacrimal punctum occlusion or tem-
porary tarsorrhaphies may become necessary [61, 71].
Glucocorticoid (GC) therapy is well established, al-
though its benefits remain unproven in large prospective
studies. The EUGOGO guidelines recommend prophy-
laxis of 0.3-0.5 ml prednisone/kg body weight in those
undergoing radioiodine ablation of the thyroid who are at
high risk of progression or de novo development of TAO.
Lower risk patients may receive reduced GC doses [60].
GCs continue to be the first-line treatment of moderate-
to-severe active TAO with unpredictable results. The rec-
ommended cumulative dose of intravenous GCs should
not exceed 8.0 g (4.5 g as intermediate-dose and 7.5 g as a
high-dose regimen for the worst cases) with carefully
controlled diabetes and hypertension [60]. In special situa-
tions such as hepatic dysfunction, cardiovascular morbid-
ity or psychiatric disorders, intravenous GCs should be
avoided. Patients with severe reduction of visual acuity,
visual field deficits, color desaturation or afferent pupillary
defects are at risk for DON and must be treated promptly
with high-dose systemic corticosteroids. In these cases,
EUGOGO recommends intravenous methylprednisolone
500-1000 mg for 3 consecutive days or alternate days
during the first week [60]. Should this prove ineffective,
emergency orbital decompression surgery may become
necessary [61]. GC can be administered orally, intraven-
ously, or locally injected into the orbit [62].
Efficacy of intravenous and oral GCs were compared
in moderately severe TAO patients; parenteral steroids
were more effective in reducing CAS by at least 3 points,
improvement in visual acuity, and decreasing disease ac-
tivity at 3 months [62, 65]. In another study, GCs in-
duced complete visual recovery in DON, improved
visual acuity, color sensitivity, and normalized visual
field defects after 2 weeks of treatment [72]. Combined
parenteral and oral GCs were effective with a low rate of
side-effects [73]. Intravenous administration appears
more efficacious and is better tolerated than orally ad-
ministered GCs [65, 74].
Radiation therapy (RT) has been reassessed recently in
combination with GCs and was found to improve
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symptoms more than GCs alone [75]. While those re-
sults were promising, a controlled study will be
necessary.
The effectiveness of alternative therapies for TAO is
being studied, frequently in pilot, inadequately powered
studies. B and T cell depletion, insulin-like growth
factor-1 (IGF-I) receptor blockers, TSHR antagonists,
and various cytokine antagonists are under scrutiny [76].
Rituximab (RTX), a monoclonal antibody recognizing
targeting CD20+ B cells, has undergone pilot clinical tri-
als with promising results in some studies [77, 78], while
another suggests no benefit [79]. In an uncontrolled
study of GC-resistant patients, RTX appeared to have
benefit [77]. Larger multicenter trials will be necessary
to establish the efficacy of RTX in TAO.
Potential for IGF-I receptor inhibition as therapy
for TAO
TSHR involvement in the pathogenesis of GD is well
established, although clarifying its role in TAO remains
to be accomplished. IGF-IR is over-expressed by orbital
fibroblasts, T cell and B cells in GD, and thus may also
participate in the disease [78, 80–83]. Both TSHR and
IGF-IR appear to be activated by immunoglobulins that
have been detected in GD (GD-IgGs). Tsui et al. [81] re-
ported that crosstalk between TSHR and IGF-IR is crit-
ical to the downstream signaling initiated by TSHR
activation. Fibrocytes express even higher levels of TSHR
than do orbital fibroblasts [84, 85]. A very recent study
confirmed the cross-talk occurring between IGF-IR and
TSHR [82]. Activating anti-IGF-IR antibodies have been
detected in some studies but not in others, leaving these
concepts controversial [80, 81, 85]. Teprotumumab, an
IGF-IR blocking monoclonal antibody, attenuates the in-
duction by TSH and TSIs of cytokines in fibrocytes [84].
The antibody has been examined for its potential thera-
peutic benefits in a multicenter, placebo-controlled clin-
ical trial of active, moderate to severe TAO [http://
clinicaltrials.gov/show/NCT01868997]. Results from this
study should be available in the next few months.
Cytokines represent potentially important therapeutic
targets in active TAO [86]. Tocilizumab, a recombinant,
humanized monoclonal antibody that antagonizes the IL-
6 receptor, was administered intravenously to eighteen pa-
tients with TAO who had proven refractory to intravenous
GC in an uncontrolled trial [87]. Improvement of CAS
was observed in all subjects, proptosis decreased in 72%,
and ocular motility improved in 83.3%. No severe side ef-
fects or relapses of active TAO were observed at the end
of a follow-up period of at least 9 months. One patient
with compressive optic neuropathy improved, avoiding
orbital decompression. Further studies involving well-
controlled, randomized and masked trials of this and other
anti-cytokine candidates will be necessary in determining
whether these approaches might be effective.
Remediation in stable TAO
Most surgical treatments for TAO are reserved for in-
active disease. The notable exceptions are active cases
which require urgent orbital decompression surgery for
DON or sight-threatening optical surface damage. Once
the stable phase has been reached, treatments are largely
surgical, aiming at anatomic, functional, and cosmetic
rehabilitation. Surgeries are typically staged and planned
individually, depending on dysfunction and disfigurement
[61]. Decompression surgery, strabismus surgery, lid
lengthening and cosmetic periorbital surgeries, may be re-
quired. These should follow this particular sequential
order since the outcome of each procedure may determine
the necessary goals of the next [60].
Different decompression techniques have been devel-
oped. Their use should be tailored to the specific thera-
peutic goals of each case. Bone and fat removal may be
performed separately or combined to maximize decom-
pression. Modern approaches include infero-medial wall,
lateral wall, and combined (balanced) decompressions. In
general, the appropriate decompression procedure is one
that will result in the degree of proptosis reduction that is
sought [4] (Fig. 1). Lateral and medial wall approaches
offer both advantages and drawbacks. For instance, lateral
wall decompression is accompanied by less post-operative
strabismus but a longer convalescence period. Further,
medial wall procedures can frequently accomplish greater
proptosis reduction [88]. Strabismus/diplopia may be
worsened by decompression and thus may require add-
itional intervention. Minimally invasive approaches have
been advocated by some [60, 89]. Endoscopic techniques
may allow decompression with less morbidity, accessing
areas with good visibility and less exposure. Purely endo-
scopic procedures and intraoperative surgical tailoring
with personalized boney decompression have resulted in
good outcomes [90]. These procedures can reduce intra-
ocular tension and provide pain relief, improve strabismus
and correct postural visual obscuration in patients with
orbital and optic nerve microvasculopathy [90]. The most
common surgical complications include de novo onset or
worsening of preexisting strabismus and globe dystopia
[89, 91]. Despite normalization of visual acuity and reso-
lution of optic nerve head edema, almost half of patients
with substantial nerve damage will manifest persistent vis-
ual field defects following adequate decompression [90].
On the other hand, improvement in severe vision loss as
late as 3-month after onset has been reported following
decompression, suggesting that the procedure may be ef-
fective in reversing DON in patients with NLP vision [92].
Criteria with which to judge success of strabismus sur-
gery in TAO are poorly defined. These procedures lack
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standardization, making surgical outcomes difficult to
compare. GO-QoL may be useful in assessing surgical
outcomes [93]. At least one study demonstrated improved
GO-QoL score following strabismus surgery in TAO [94].
Upper eyelid retraction is the most common clinical
sign in TAO. It is frequently improved but rarely com-
pletely corrected following orbital decompression [62, 71].
Several techniques have been developed for correcting
Fig. 1 Patients with thyroid-associated ophthalmopathy before (1a, 2a, 3a, 4a) and after (1b, 2b, 3b, 4b) surgical treatment. These images exemplify the
most common signs of ophthalmopathy, including proptosis, conjunctival hyperemia, periocular edema and upper and lower eyelid retraction. These may
improve with treatment. These images were generously provided by Dr. Raymond Douglas, Kellogg Eye Center, University of Michigan, Ann Arbor, USA
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upper eyelid retraction. These aim at weakening retractor
muscles, by recession, partial resection, or lengthening
[24]. Surgical outcomes in upper eyelid repair are difficult
to predict and many different techniques have emerged
yielding variable results [24, 62]. Lower eyelid retraction
may also be surgically corrected; however, no consensus
as to the best approach has been reached. The surgeon’s
preferences and expertise, anatomical variations, outcome
expectations, attitude towards intervention, and disease
severity should guide the choice of surgical method [91].
Conclusions
Nearly two hundred years after the first descriptions of
GD, we continue to discover more about TAO, its mo-
lecular underpinnings, clinical behavior, and attempt to
identify improved therapies. Advancing research tech-
niques have led us to clearer insights into this vexing
disorder. But substantial barriers remain, including the
absence of proven animal models possessing the neces-
sary fidelity to human disease, better access to affected
tissue, and more aggressive organization of large, multi-
center clinical trials. Ultimately, our goal must focus on
restoring immune tolerance to the autoantigens that
underlie the disease. That approach will spare many pa-
tients the adverse effects of chronic immune suppression
and the invasive surgical approaches currently employed.
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